Educational information on eye health, nutrition and lifestyle as a possible complementary support to standard ophthalmic care. No content replaces medical visits, diagnosis or prescribed therapies.

Topical Insulin Eye Drops

Sterile compounded preparation to support corneal epithelial repair.
Specialized therapeutic option for refractory ocular surface conditions.

What it is and how it works on the cornea

Topical insulin is a compounded ophthalmic preparation used for selected ocular surface diseases characterized by impaired epithelial healing. The cornea features specific receptors through which insulin promotes tissue regeneration. It is not an eye drop "for diabetes" nor a generic treatment for common dry eye, but a targeted re-epithelialization support prescribed by a specialist.

When It Is Considered

Clinical applications strictly evaluated by the Ophthalmologist.

Topical insulin is assessed when conventional therapies fail to heal the cornea:

1
Neurotrophic Keratitis

Reduced corneal sensitivity and impaired tissue self-repair.

2
Persistent Epithelial Defects

Refractory corneal ulcers (PED) that fail to close.

3
Diabetic Keratopathy

Structural ocular surface alterations in metabolic profiles.

4
Severe Dry Eye

Dry eye disease with severe associated epithelial damage.

Approfondisci →
5
Recurrent Corneal Erosions

Defect in epithelial adhesion to the basement membrane.

6
Indolent Corneal Ulcers

Surface lesions showing no signs of spontaneous healing.

7
Chemical Burn Sequelae

Post-acute regenerative phase following thermal/chemical damage.

8
Refractory Toxic Damage

Epithelial suffering secondary to prolonged abuse of preserved drops.

Scientific Evidence and Mechanisms

Recent systematic reviews (2025-2026) highlight that topical insulin promotes high re-epithelialization rates. While promising, it remains an emerging therapy requiring tailored protocols.

Dati Biochimici
Receptor Stimulation

Binds to corneal receptors promoting cellular migration.

Microenvironment Modulation

Acts on signaling pathways regulating epithelial integrity.

Systemic Safety

Topical dosages studied have shown no clinical impact on blood glucose.

Biological Approaches: Autologous Serum

In severe keratopathies, another high-profile regenerative option evaluated by specialists is autologous serum eye drops, a blood-derived therapy rich in growth factors.

Discover Autologous Serum →

Compounding and Safety Precautions

What to know about prescriptions, pharmacy preparation, and home care.

1
Medical Prescription

Strictly requires an ophthalmologist's prescription; not over-the-counter.

2
Compounding Pharmacy

Prepared exclusively by authorized compounding pharmacies with sterile facilities.

3
Storage

Often requires refrigeration; always follow the pharmacist's label instructions.

4
Tolerability

May cause transient burning; immediately report increased pain or photophobia.

Clinical Facts vs Myths

Clarifying the real medical use of ophthalmic insulin:

TopicMyth (Incorrect)Medical Fact (Reality)
PurposeCures systemic diabetes through the eyesActs locally to regenerate the corneal epithelium
AvailabilityCan be bought ready-made over the counterIt is a sterile custom-compounded medication
Universal UseReplaces artificial tears for mild dry eyeReserved for severe and refractory corneal damage
Glycemic EffectsAlters blood glucose levels systemicallyNo relevant systemic effects emerge from clinical data

Dosages (U/mL) and treatment duration are individually tailored by the specialist.

Beyond the Symptom: Systemic Ophthalmology

An epithelial defect is not merely "intense dry eye". It indicates a vulnerable surface that may conceal neuro-inflammation, eyelid alterations, or systemic imbalances. Topical insulin provides targeted regenerative support, but long-term success lies within Systemic Ophthalmology: assessing the patient's biological terrain, immune axis, and root causes.

Frequently Asked Questions

Clinical studies published to date have shown no relevant systemic effects or hypoglycemia linked to its ophthalmic use.

Not yet. Although pharmaceutical patents emerged recently, it is currently only accessible via pharmacy compounding.

No. Acute trauma or suspected infections require immediate targeted antibiotics and emergency care, not epithelial stimulators.
Scientific References & Bibliography
  • Radulescu RB, Ferrari S, Stanca HT, Ponzin D. Topical insulin as a novel treatment for persistent epithelial defects and other ocular surface disorders: a systematic review. Graefes Arch Clin Exp Ophthalmol. 2025. PubMed
  • Burgos-Blasco B, et al. Topical insulin, a novel corneal epithelial regeneration agent in dry eye disease. Eur J Ophthalmol. 2024. PubMed
  • Farmagalenica. Insulina collirio: farmaco galenico in Farmacia. Practical information on sterile compounding and storage. Article Link

Avvertenza Clinica e Deontologica

Deontological Notice: Information is for educational purposes. Insulin eye drops represent an emerging compounded therapeutic option, not a universal standard cure. Requires clinical diagnosis.

Network Oculistica Sistemica Italiano

Oculistica Sistemica
Visit site
Microbiota Oculare
Visit site
Nutrizione Oculistica
Visit site
Eye Longevity
Visit site
Medici Oculisti
Visit site